E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
ATRIAL FIBRILLATION IN PATIENTS AFTER OCCLUSION OF THE LEFT ATRIAL APPENDAGE (LAAC) |
FIBRILACIÓN AURICULAR EN PACIENTES DESPUÉS DEL CIERRE DE OREJUELA IZQUIERDA |
|
E.1.1.1 | Medical condition in easily understood language |
ATRIAL FIBRILLATION |
FIBRILACIÓN AURICULAR |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
TO DEMONSTRATE SUPERIORITY OF A STRATEGY OF ANTICOAGULATION WITH APIXABAN 5 MG/2.5 MG BID AS COMPARED WITH THE CURRENT STANDARD OF CARE (DUAL ANTIPLATELET THERAPY) AFTER OCCLUSION OF THE LEFT ATRIAL APPENDAGE (LAAC) IN PATIENTS WITH ATRIAL FIBRILLATION |
EL OBJETIVO DEL ESTUDIO ES DETERMINAR CUÁL ES EL MEJOR TRATAMIENTO MÉDICO TRAS EL IMPLANTE DE UN DISPOSITIVO DE CIERRE DE OREJUELA TIPO AMULET. EL TRATAMIENTO TRAS EL CIERRE DE OREJUELA EN PACIENTES EN LOS QUE LA INDICACIÓN DE CIERRE HA SIDO UN EVENTO HEMORRÁGICO NO HA SIDO ADECUADAMENTE ESTUDIADA Y NO EXISTEN EN LA ACTUALIDAD DATOS SUFICIENTES PARA ESTABLECER CUAL ES EL TRATMIENTO QUE HAN DE RECIBIR ESTOS PACIENTES. POR ELLO EN EL ESTUDIO ADALA SE COMPARAN EL TRATAMIENTO QUE SE PAUTABA HABITUALMENTE (DOBLE ANTIAGREGACIÓN CON ASPIRINA Y CLOPIDOGREL) FRENTE A UN ANTICOAGULANTE ORAL DE NUEVA GENERACIÓN A DOSIS REDUCIDA (APIXABAN) |
|
E.2.2 | Secondary objectives of the trial |
TO DEMONSTRATE SUPERIORITY OF A STRATEGY OF ANTICOAGULATION WITH APIXABAN 5 MG/2.5 MG BID AS COMPARED WITH THE CURRENT STANDARD OF CARE (DUAL ANTIPLATELET THERAPY) AFTER OCCLUSION OF THE LEFT ATRIAL APPENDAGE (LAAC) IN PATIENTS WITH ATRIAL FIBRILLATION |
TO DEMONSTRATE SUPERIORITY OF A STRATEGY OF ANTICOAGULATION WITH APIXABAN 5 MG/2.5 MG BID AS COMPARED WITH THE CURRENT STANDARD OF CARE (DUAL ANTIPLATELET THERAPY) AFTER OCCLUSION OF THE LEFT ATRIAL APPENDAGE (LAAC) IN PATIENTS WITH ATRIAL FIBRILLATION |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age> 18 years • NVAF (paroxysmal, persistent or permanent) • CHADS2 score ≥1 or CHA2DS2-VASc score ≥2 * Adequate anatomy for LAA closure and contraindication for OAC (absolute or relative). • Able to give informed consent and to be followed-up (phone and clinical visit) |
• Edad> 18 años • FANV (paroxística, persistente o permanente) • Escala CHADS2 ≥ 1 o Escala CHA2DS2-VASc ≥ 2 • Adecuada anatomía para cierre de orejuela izquierda LAA y contraindicación para ACO (absoluta o relativa) • Estar capacitado para dar el consentimiento informado y realizar los seguimientos telefónicos y las visitas clínicas. |
|
E.4 | Principal exclusion criteria |
• Patients with mechanical prostheses, evidence of thrombus, complex aortic atheroma or symptomatic carotid disease • Contraindication for TEE studies • Platelets <40000 • Absolute contraindication to Apixaban for 3 months (severe renal failure with Cl. creat <15 ml / h or severe liver disease Child B or C) or allergy to the drug. Contraindication to any form of anticoagulation or antiplatelet therapy. • Patients with a history of drug or alcohol abuse, or psychosocial reasons that preclude the follow-up of the patient. •Women of childbearing potential (WOCB) |
• Pacientes con prótesis mecánicas, evidencia de trombo intracavitario, ateroma aórtico complicado o enfermedad carotídea sintomática • Contraindicación para la realización de eTE seriados • Plaquetas <40000 • Contraindicación absoluta para el tratamiento con apixaban durante tres meses (insuficiencia renal severa con CICreat<10 ml/h o hepatopatía severa Child B o C) o alergia a algunos de los fármacos. • Contraindicación a cualquier forma de terapia anticoagulante o antiplaquetaria • Pacientes con historial de abuso de drogas o alcohol, o características psicológicas que impidan el seguimiento del paciente • Mujeres con potencial de quedarse embarazadas. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
COMBINED OF EFFICACY (THROMBOEMBOLIC EVENTS PREVENTION AND DEVICE THROMBOIS) AND SAFETY (MAJOR BLEEDING INCIDENCE) AT 3 MONTHS WITH BOTH STRATEGIES. |
COMBINADO DE EFICACIA ( PARA LA PREVENCIÓN DE EVENTOS TROMBOEMBÓLICOS CLÍNICOS Y TROMBOSIS DE DISPOSITIVO) Y SEGURIDAD (PARA LA INCIDENCIA DE SANGRADOS MAYORES) A LOS TRES MESES ENTRE LAS DOS ESTRATEGIAS. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
ASPIRINA Y CLOPIDOGREL |
AAS AND CLOPIDOGREL |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVSL |
ÚLTIMA VISITA DEL ÚLTIMO PACIENTE |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 12 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |